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Introduction {#sec005}
============

Type 2 diabetes (T2DM) has become a major public health problem in China. In 2009, the age-standardized prevalences of total diabetes and prediabetes were 9.7% and 15.5%, respectively, accounting for 92.4 million adults with diabetes and 148.2 million adults with prediabetes \[[@pone.0130665.ref001]\]. Diabetic retinopathy (DR) is the most frequent cause of new cases of blindness among adults aged 20--74 years\[[@pone.0130665.ref002]\]. Approximately 29% of U.S. adults with type 2 diabetes have DR \[[@pone.0130665.ref003]\]. Liu et al \[[@pone.0130665.ref004]\] reported that 14.8% Chinese patient with T2DM have DR.

The presence of DR was associated with an increased risk of all-cause mortality and cardiovascular events in diabetic patient \[[@pone.0130665.ref005]\]. Up to 21% of patients with T2DM have retinopathy at the time of first diagnosis of diabetes, and most develop some degree of retinopathy over time. Vision loss due to diabetic retinopathy results from several mechanisms and central vision may be impaired by macular edema or capillary nonperfusion\[[@pone.0130665.ref006]\]. Although the major risk factors for DR (e.g., hyperglycemia, hypertension, dyslipidemia) have been examined in many epidemiologic studies and clinical trials, there is considerable variation inthe consistency, pattern, and strength of these risk factors \[[@pone.0130665.ref003]\].

Mannose-binding lectin (MBL) is synthesized by hepatocytes and belongs to the family of C-type lectins\[[@pone.0130665.ref007]\]. MBL is a part of the complement cascadeand plays an important role in the first line of defense ofthe innate immune system against pathogenicmicroorganisms \[[@pone.0130665.ref008]\]. MBL exerts an important role in the innate immune system \[[@pone.0130665.ref009]\], and several studies have indicated that low levels of MBL affect the outcome of kidney graft survival \[[@pone.0130665.ref010]\], infectious diseases \[[@pone.0130665.ref011]\], critical illness \[[@pone.0130665.ref012]\] and neonatal sepsis and pneumonia \[[@pone.0130665.ref013]\]. Interestingly, high levels of MBL offer protection against invading microorganisms and may in other situations confer biological disadvantages \[[@pone.0130665.ref014]\]. MBL may aggravate local and systemic inflammation throughcomplement activation and modulation of proinflammatory cytokine production \[[@pone.0130665.ref015]\]. Previous studies have suggested that increased MBL levels are associated with an increased risk of stroke and poor functional outcomes after stroke in Chinese population \[[@pone.0130665.ref016]--[@pone.0130665.ref017]\].

There have been great controversies in studying relationship between MBL and diabeticcomplications. Siezenga et al. \[[@pone.0130665.ref018]\] found that log MBL levels were not associated with the occurrence of cardiovascular events in type 2 diabetic South Asians, while Elawa et al \[[@pone.0130665.ref019]\] reported that elevated serum MBL in T2DM patients indicated a possible poor diabetic control and bad progression of the disease with possibility of the presence. Consistent with this, Bouwman et al. \[[@pone.0130665.ref020]\]concluded that MBL serum concentration and complex activity are increased in early-onset diabetic patients upon manifestation independently of genetic predisposition to high MBL production, indicating a possible role in the immunopathogenesis of type 1 diabetes. In addition, Hansen et al \[[@pone.0130665.ref021]\] found that the median MBL concentration was higher in type 1 diabetic patients than in healthy controls. However, no data are available on the role of MBL in the progression of DR in Chinese patients with T2DM. In this study, we therefore evaluated serum MBL levels in Chinese type 2 diabetic patients with and without diabetic retinopathy.

Method {#sec006}
======

We conducted a prospective cohort study at the endocrinology department of our hospital. We consecutively recruited 324 Chinese with type 2 diabetes aged 31--74 years between October 2012 and May 2014. Participants were excluded if they had a history of epilepsy or glaucoma, had undergone previous vitreal surgery, and/or had a cataract on examination. Participants who had no light perception or severe visual impairment in both eyes or had a severe infection in one or both eyes were excluded. A group of 300 age-matched healthy subjects served as control subjects. The study followed the tenets of the Declaration of Helsinki and was approved by the Institute ethics committee of Zhongnan Hospital, Wuhan University, with written informed consent obtained from each participant.

We used the Canon CR6-45NM ophthalmic digital imaging system and Canon EOS 10D digitalcamera (Canon, Tokyo, Japan) to take 2 digital images per eye through a nonpharmacologicallydilatedpupil. DR was defined as the presence of 1 or more retinal microaneurysms or retinal blot hemorrhages with or without more severe lesions (hard exudates, soft exudates, intraretinalmicrovascular abnormalities, venous beading, retinal new vessels, preretinal and vitreous hemorrhage, and fibroproliferans) using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading standards\[[@pone.0130665.ref022]\]. DR severity was categorized as non-proliferative diabetic retinopathy (NPDR; level 20 through level 53) and proliferative diabetic retinopathy (PDR; level≥60). Diabetic macular edema (DME) was defined as present or absent and classified as with or without clinically significant macular edema; and vision-threatening diabetic retinopathy (VTDR) was defined as the presence of PDR and/or DME. T2DM was defined as self-report of a previous diagnosis of the disease by a clinician (excluding gestational diabetes mellitus) or hemoglobin A1c (HbA1c) of 6.5% or greater \[[@pone.0130665.ref023]\]. At baseline, we requested individual participant data regarding presence and severity of DR, DME status, age, sex, ethnicity, diabetes type and duration, HbA1c, systolic and diastolic blood pressure, cigarette smoking status, BMI, and current use of diabetes, antihypertensive, and lipid-lowering medications.

Blood samples of patients and controls were obtained at 7:00 AM in the next morning of the day of inclusion under fasting state. 2 ml of blood were placed into a dry clean tube and left to clot at room temperature, and then separated by centrifugation for 15 min. Clotted blood was centrifuged within 1h and serum stored at -80°C. HbA1c was measured by high-performance liquid chromatography (HLC-723 G7; TOSHO, Japan) with a normal range of 4--6%. MBL was measured by time-resolved immune-fluorometricassay on serum samples. Microwells coated with anti-MBL antibody were incubated with dilutions of patient serum, were developed with europium-labelled anti-MBL antibody, and europium was quantified with time-resolved fluorometric assay (Baoman Biological Technology Co., Ltd, Shanghai, China). The detection limit was 1.8ug/L. The standard concentrations in these kits range from 1.8 to 100ug/L, providing a range of 180--10000ug/L at 1/100 dilution. The coefficients of variation (CV) for the intra- and inter-assay reproducibility are 4.0--5.8% and 6.7--9.4%, respectively.

Results are expressed as percentages for categorical variables and as medians (interquartile ranges, IQRs) for the continuous variables. Univariate data on demographic and clinical features were compared by Mann-Whitney U-test or Chi-Square test as appropriate. Correlations among continuous variables were assessed by the Spearman rank-correlation coefficient. To investigate whether MBL allows predicting of both DR and VTDR in diabetes different statistical methods were used. First, the relation of MBL with the two points was investigated with the use of logistic regression models. Therefore, common logarithmic transformation (ie, base 10) was performed to obtain normal distribution for skewed variables (ie, MBL concentrations) as the resulting model yielded smaller Akaike Information Criterion, which was chosen to compare the results. We used crude models and multivariate models adjusted for all significant predictors and report odds ratios (ORs). For multivariate analysis, we included confounders, known risk factors, and other predictors as assessed in univariate analysis. Second, receiver operating characteristic curves (ROC) was used to test the overall predict accuracy of MBL and other markers, and results were reported as area under the curve (AUC). All statistical analysis was performed with SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA)and the ROCR package (version 1.0--2), which is available from CRAN repository (<http://cran.r-project.org/>). Statistical significance was defined as P\< 0.05.

Results {#sec007}
=======

Patient Characteristics {#sec008}
-----------------------

There were 324 people with type 2 diabetes eligible for the study. The median age of patients included in this study was 55(IQR, 42--68) years and 55.6% were men. The median time of diabetes duration was 7.5 (IQR, 6.0--10.0) years. DR was found in 115 patients (35.5%). Forty-one patients were defined as VTDR, thus the rate was 12.7%. Basal characteristics of those patients were provided in [table 1](#pone.0130665.t001){ref-type="table"}.

10.1371/journal.pone.0130665.t001

###### Basal characteristic of diabetes patients with DR or without DR.

![](pone.0130665.t001){#pone.0130665.t001g}

                                        Diabetes           Retinopathy status                      
  ------------------------------------- ------------------ -------------------- ------------------ ----------
  Age at baseline (IQR, years)          55(42--68)         56(42--68)           55(43--67)         NS
  Male (%)                              55.6               52.2                 57.4               NS
  Diabetes duration (IQR, years)        7.5(6.0--10)       9.0(8.0--12.5)       6.0(4.5--8.0)      \<0.001
  BMI (IQR, kg/m2)                      29.1(26.5--31.4)   29.5(26.9--31.8)     28.4(25.6--31.1)   NS
  Systolic blood pressure (IQR, mmHg)   134(127--144)      145(132--150)        122(115--135)      \<0.01
  Smoking status (%)                    40.1               39.1                 40.7               NS
  Current alcohol intake (%)            34.6               34.8                 34.4               NS
  Intensive glucosetreatment (%)        41.7               47.8                 38.3               \<0.01
  Blood pressuretreatment (%)           37.7               38.3                 37.3               NS
  Use of lipid-lowering medication(%)   33.3               32.2                 33.9               NS
  Laboratory findings(IQR)                                                                         
   HbA1c (%)                            7.9(7.1--8.7)      8.5(7.6--9.7)        7.2(6.4--8.1)      \<0.001
   Serum creatinine (umol/L)            92(75--100)        94(77--103)          87(74--97)         NS
   Total cholesterol (mmol/L)           4.7(3.9--5.5)      4.9(4.2--5.7)        4.4(3.7--5.2)      \<0.01
   Triglycerides (mmol/L)               1.5(0.9--1.8)      1.6(1.0--1.9)        1.4(0.9--1.7)      NS
   LDL-cholesterol (mmol/l)             2.6(1.9--3.0)      2.6(2.1--3.1)        2.5(1.9--2.9)      NS
   HDL-cholesterol (mmol/l)             1.5(1.3--1.7)      1.6(1.4--1.8)        1.5(1.2--1.7)      NS
   Hs-CRP(mg/dL)                        0.98(0.44--2.10)   1.48(0.62--3.01)     0.62(0.32--1.57)   \<0.001
   MBL(ug/L)                            2976(2421--3521)   3388(2942--4080)     2653(2157--3110)   \<0.0001
  Any DR (%)                            35.5               ---                  ---                ---
   PDR                                  8.0                                                        
   DME                                  9.3                                                        
   VTDR                                 12.7                                                       

Results are expressed as percentages or as medians (IQR); BMI, body mass index; Hs-CRP, High-sensitivity- C-reactive protein; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DME, diabetic macular edema; VTDR; vision-threatening diabetic retinopathy.

MBL and Clinical Varies {#sec009}
-----------------------

The results indicated that the serum MBL levels were significantly (P\<0.0001) higher in diabetes patients as compared to normal cases \[2976(IQR, 2421--3521μg/L); 732(IQR, 576--894μg/L), respectively; [Fig 1](#pone.0130665.g001){ref-type="fig"}\]. There was a modest positive correlation between levels of MBL and HbA1c (r = 0.385, P\<0.0001; [Fig 2A](#pone.0130665.g002){ref-type="fig"}). In addition, there was a significant, albeit weak, positive correlation between MBL levels and Hs-CRP (r = 0.159, P = 0.004; [Fig 2B](#pone.0130665.g002){ref-type="fig"}). Furthermore, there was no correlation between serumlevels of MBL and others factors, such as, sex, age, creatinine, triglyceride, cholesterol, LDL and HDL, duration of diabetes, or daily insulin dose(P\>0.05).

![A separate histogram of serum MBL levels in diabetic patientsand normal controls.\
The horizontal lines in the top indicate mean levels.*P*values refer to Mann-Whitney *U* tests for differencesbetween groups.](pone.0130665.g001){#pone.0130665.g001}

![Correlation between the serum MBL levels and other factors (a) Correlation between the serum MBL levels and HbA1c; (b) Correlation between the serum MBL levels and Hs-CRP.](pone.0130665.g002){#pone.0130665.g002}

MBL and DR {#sec010}
----------

In the 115 patients with DR, serum MBL levels were higher compared with those in patients without DR \[3388(IQR, 2942--4080) μg/L vs. 2653(IQR, 2157--3110) μg/L; P\<0.0001; [Fig 3A](#pone.0130665.g003){ref-type="fig"}). In univariate logistic regression analysis, we calculated the odds ratio (OR) of log-transformed MBL levels as compared with other risk factors as presented in [Table 2](#pone.0130665.t002){ref-type="table"}. With an unadjusted OR of 7.12 (95% CI, 3.81--13.15), MBL had a strong association with DR. After adjusting for all other significant predictors, MBL remained can be seen as an independent DR predictor with an adjusted OR of 3.45 (95% CI, 1.42--7.05; P\<0.0001). In multivariate analysis, there was an increased risk of DR associated with MBL levels≥3521ug/L(3^rd^quartiles; OR 3.10, 95% CI: 1.72--5.48; P\<0.0001) after adjusting for possible confounders. In addition, male sex, diabetes duration, HbA1c, Hs-CRP, intensive glucose treatment and systolic BP were also can be seen as DR predictors in multivariate analysis ([Table 2](#pone.0130665.t002){ref-type="table"}).

![Distribution of serum MBL levels in diabetic patients with different groups.\
The horizontal lines indicate mean levels. (A) Distribution of serum MBL levels in diabetic patients with DR and without DR; (B) Distribution of serum MBL levels in diabetic patients withvision-threatening diabetic retinopathy (VTDR) and without VTDR. P values refer to Mann-Whitney U tests for differences between groups.](pone.0130665.g003){#pone.0130665.g003}

10.1371/journal.pone.0130665.t002

###### Univariate and multivariate logistic regression analysis for DR and VTDR.

![](pone.0130665.t002){#pone.0130665.t002g}

  Parameter                                                      Univariate Analysis   Multivariate Analysis                                   
  -------------------------------------------------------------- --------------------- ----------------------- ---------- ------ ------------- ----------
  Predictor: DR                                                                                                                                
   MBL[^b^](#t002fn002){ref-type="table-fn"}                     7.12                  3.81--13.15             \<0.0001   3.45   1.42--7.05    \<0.0001
   MBL(≥3^rd^quartiles) [^c^](#t002fn003){ref-type="table-fn"}   3.92                  2.31--6.56              \<0.0001   3.10   1.72--5.48    \<0.0001
   Male sex                                                      1.20                  1.05--1.38              0.005      1.15   1.06--1.28    0.002
   HbA1c                                                         1.08                  1.03--1.20              \<0.001    1.05   1.01--1.16    \<0.001
   Diabetes duration                                             1.24                  1.13--1.30              \<0.0001   1.16   1.10--1.24    \<0.0001
   Hs-CRP                                                        1.10                  1.04--1.18              \<0.001    1.08   1.03--1.18    \<0.001
   Intensive glucosetreatment                                    2.03                  1.25--3.45              0.018      1.90   0.91--3.15    0.311
   Hypertension                                                  1.58                  1.31--1.82              0.009      1.30   1.12--1.44    0.011
  Predictor: VTDR                                                                                                                              
   MBL [^b^](#t002fn002){ref-type="table-fn"}                    9.14                  3.16--1.8.22            \<0.0001   4.42   1.51--8.18    \<0.0001
   MBL(≥3^rd^quartiles)[^c^](#t002fn003){ref-type="table-fn"}    9.55                  4.51--19.78             \<0.0001   7.83   3.35--18.31   \<0.0001
   Male sex                                                      1.16                  1.06--1.46              0.031      1.08   1.02--1.35    0.037
   HbA1c                                                         1.12                  1.04--1.33              \<0.001    1.08   1.03--1.16    \<0.001
   Diabetes duration                                             1.22                  1.08--1.36              \<0.0001   1.12   1.04--1.25    \<0.0001
   Hs-CRP                                                        1.14                  1.06--126               0.003      1.09   1.03--1.18    0.006
   Intensive glucosetreatment                                    1.22                  1.09--1.54              \<0.001    1.14   1.06--1.28    0.003
   Hypertension                                                  1.71                  1.27--3.01              0.009      1.58   1.28--2.30    0.006

^a^Note that the odds ratio corresponds to a unit increase in the explanatory variable.

^b^log-transformed, note that the odds ratio corresponds to a log-unit increase in the explanatory variable

^c^ MBL(≥3^rd^quartiles) as one predictor in the multivariate logistic regression analysis

OR, odds ratio; CI, confidence interval; Hs-CRP, High-sensitivity- C-reactive protein;DR, diabetic retinopathy; VTDR; vision-threatening diabetic retinopathy.

With an AUC of 0.84 (95% CI, 0.80--0.89), MBL showed a significantly greater discriminatory ability to diagnose DR as compared with Hs-CRP (AUC, 0.58; 95% CI, 0.52--0.65; P\<0.0001), HbA1c (AUC, 0.63; 95% CI, 0.56--0.70; P\<0.001) and age (AUC, 0.55; 95% CI, 0.49--0.63; P\<0.0001), while was in the range of diabetes duration (AUC, 0.82; 95% CI, 0.77--0.86; P = 0.056; [Fig 4A](#pone.0130665.g004){ref-type="fig"}). Interestingly, MBL improved the ability of diabetes duration to diagnose DR (AUC of the combined model, 0.88; 95% CI, 0.82--0.96; P\<0.01). This improvement was stable in an internal 5-fold cross validation that resulted in an average AUC (standard error) of 0.82 (0.030) for the diabetes duration and 0.88(0.021) for the combined model, corresponding to a difference of 0.06(0.009). [Table 3](#pone.0130665.t003){ref-type="table"}.

![Receiver operating characteristic (ROC) curves were utilized to evaluate the accuracy of markers to diagnoseDR or VDTR.\
(A) Receiver operator characteristic curve demonstrating sensitivity as a function of 1-specificity for diagnosing the DR based on the MBL, Hs-CRP, HbA1c anddiabetes duration; (B) Receiver operator characteristic curve demonstrating sensitivity as a function of 1-specificity for diagnosing the VDTR based on the MBL, Hs-CRP, HbA1c anddiabetes duration.](pone.0130665.g004){#pone.0130665.g004}
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###### Receiver operating characteristics curve analysis.

![](pone.0130665.t003){#pone.0130665.t003g}

  Parameter                                              DR     VTDR                                        
  ------------------------------------------------------ ------ ------------ ---------- ------ ------------ ----------
  MBL                                                    0.84   0.80--0.89              0.86   0.80--0.92   
  Age                                                    0.55   0.52--0.65   \<0.0001   0.59   0.53--0.64   \<0.0001
  Male                                                   0.57   0.54--0.64   \<0.0001   0.60   0.54--0.66   \<0.0001
  Diabetes duration                                      0.82   0.77--0.86   0.056      0.85   0.77--0.92   0.126
  Systolic blood pressure                                0.60   0.55--0.66   \<0.0001   0.62   0.57--0.69   \<0.0001
  HbA1c                                                  0.63   0.56--0.70   \<0.0001   0.69   0.60--0.78   \<0.0001
  Hs-CRP                                                 0.58   0.52--0.65   \<0.0001   0.61   0.53--0.70   \<0.0001
  Combined model[^a^](#t003fn002){ref-type="table-fn"}   0.88   0.82--0.96   \<0.01     0.90   0.83--0.96   \<0.01

AUC, areaunder the curve;CI, confidence interval; OR, odds ratio; Hs-CRP, High-sensitivity- C-reactive protein; DR, diabetic retinopathy; VTDR; vision-threatening diabetic retinopathy.

^a^Combined model = MBL and diabetes duration

MBL and VTDR {#sec011}
------------

In the 41 patients with VTDR, serum MBL levels were higher compared with those in patients without DR \[4087(IQR, 3360--4290) μg/L vs. 2852(IQR, 2234--3325) μg/L; p\<0.0001; [Fig 3B](#pone.0130665.g003){ref-type="fig"}). In univariate logistic regression analysis, we calculated the odds ratio (OR) of log-transformed MBL levels as compared with other risk factors as presented in [Table 2](#pone.0130665.t002){ref-type="table"}. In multivariate analysis, after adjusting for all other significant predictors, MBL remained can be seen as an independent DR predictor with an adjusted OR of 4.42 (95% CI, 1.51--8.18; P\<0.0001). In addition, there was an increased risk of DR associated with MBL levels≥3521ug/L(3^rd^quartiles; OR 7.89, 95% CI: 3.42--18.53; P\<0.0001) after adjusting for possible confounders. In addition, male sex, diabetes duration, HbA1c, Hs-CRP and systolic BP were also can be seen as DR predictors in multivariate analysis ([Table 2](#pone.0130665.t002){ref-type="table"}).

With an AUC of 0.86 (95% CI, 0.80--0.92), MBL showed a significantly greater discriminatory ability to diagnose VTDR as compared with Hs-CRP (AUC, 0.61; 95% CI, 0.53--0.70; P\<0.0001), HbA1c (AUC, 0.69; 95% CI, 0.60--0.78; P\<0.0001) and age (AUC, 0.59; 95% CI, 0.53--0.64; P\<0.001), while was in the range of diabetes duration (AUC, 0.85; 95% CI, 0.77--0.92; P = 0.126; [Fig 4B](#pone.0130665.g004){ref-type="fig"}). Again, MBL improved the ability of diabetes duration to diagnose VTDR (AUC of the combined model, 0.90; 95% CI, 0.83--0.96; P\<0.01). This improvement was also stable in an internal 5-fold cross validation that resulted in an average AUC (standard error) of 0.85 (0.022) for the diabetes duration and 0.90 (0.014) for the combined model, corresponding to a difference of 0.05(0.008; [Table 3](#pone.0130665.t003){ref-type="table"}).

Discussions {#sec012}
===========

Several studies have shown that deficiency of MBL increases the overall susceptibility of an individual to infectious disease \[[@pone.0130665.ref024]\]. The most striking example of this is the association of acute respiratory tract infections with MBL deficiency in early childhood \[[@pone.0130665.ref025]\]. Clinical studies have shown that MBL insufficiency is associated with bacterial infection in patients with neutropenia and meningococcal sepsis. Numerous other potential infectious disease associations have been described \[[@pone.0130665.ref026]\]. In contrast, there is evidence that for some intracellular parasites MBL deficiency may be protective and this might explain the high frequency of *MBL* mutations in sub-Saharan Africa and South America \[[@pone.0130665.ref024]\]. MBL is an example of a pattern recognition molecule that plays a dual role in modifying inflammatory responses to sterile and infectious injury \[[@pone.0130665.ref027]\].

Previous studies had suggested that there may be a link between complement activation and the development of diabetic complications \[[@pone.0130665.ref028]--[@pone.0130665.ref029]\]. Mounting evidence supports the importance of the MBL pathway of complement activation in innate immunity \[[@pone.0130665.ref030]\]. One study suggested that MBL and the lectin complement pathway play a significant role in vascular dysfunction and cardiomyopathy after acute hyperglycemia \[[@pone.0130665.ref031]\]. In this study, we firstly assessed the serum MBL levels with regard to their accuracy to predict DR and VTDR in patients with T2DM in Chinese sample. Consistent with our findings, Man et al. \[[@pone.0130665.ref032]\] also found that evaluated serum levels of MBL can be seen as an independent marker of DR even after correcting for possible confounding factors in type 2 diabetic patients.

In previous studies, Hansen et al. \[[@pone.0130665.ref021]\] demonstrated that circulating MBL concentrations are significantly elevated in patients with type 1 diabetes and suggested a possible role of MBL in the pathogenesis of renovascular complications in diabetes. In another study, they also found that MBL may be involved in the pathogenesis of micro-and macrovascular complications in type 1 diabetes \[[@pone.0130665.ref015]\]. In this study, we confirmed that of elevated MBL were correlated with DR and VTDR, and added significant additional predictive information to the diabetes duration, suggesting a possible role of MBL in the pathogenesis of DR complications in T2DM. Similarly, Hansen et al. \[[@pone.0130665.ref033]\] reported that in patients with type 2 diabetes, measurements of MBL alone or in combination with CRP can provide prognostic information on mortality and the development of albuminuria.

The importance of glycaemia, blood pressure and diabetes duration as risk factors for DR is already well established \[[@pone.0130665.ref034]\]. Male sex has also been reported as a risk factor in other studies \[[@pone.0130665.ref035]\]. Importantly, in our study, we found that MBL was a risk factor for DR. In addition, male sex, diabetes duration, HbA1c, Hs-CRP and systolic BP was also reported.

High CRP and MBL levels could both be a sign ofan inflammatory state, and MBL is a slower-reacting and muchweaker acute-phase reactant than CRP \[[@pone.0130665.ref017]\]. Navarro et al\[[@pone.0130665.ref036]\] found that inflammatory parameters(Hs-CRP) in patients with type 2 diabetes at an early stage of nephropathy are independently associated with urinary albumin excretion (UAE). We did indeed observesignificantly higher Hs-CRP levels among patientswith diabetic retinopathy compared with others. However, the relationship between MBL levelsand diabetic retinopathy persisted on additional adjustment for Hs-CRP, which indicates thatCRP and MBL may carry different types of information asmarkers of inflammation.

In a meta- analysis, a total of 35 studies (1980--2008) provided data from 22,896 individuals with diabetes, and the overall prevalence was 34.6% for any DR \[[@pone.0130665.ref003]\]. Similarly, in our study, 35.5% of the diabetes patients had DR. Our findings are in line with reports from recent population studies in which the prevalence of DR ranged from 6% to 33% \[[@pone.0130665.ref033], [@pone.0130665.ref037]--[@pone.0130665.ref038]\]. Zhang et al. \[[@pone.0130665.ref039]\]reported that the estimated prevalence of DR and VDTR was 28.5% (95% confidence interval \[CI\], 24.9%-32.5%) and 4.4% (95% CI, 3.5%-5.7%) among US adults with diabetes, respectively. Differences in study methodologies, population characteristics, and ascertainment and classification of DR have made direct comparisons between studies difficult.

Despite extensive research, the exact pathogenesis of DR is still unknown. Whether higher serum MBL level was acause of or merely a marker for DR in diabetesremain uncertain. MBL is more likely to be acontributing factor to the DR rather than a mere marker, and may involve multiple mechanisms. Firstly, MBL is a slower-reacting and much weaker acute-phase reactant than CRP \[[@pone.0130665.ref012]\], but it is possible that the differences in MBL concentrations between patients with and without DR may reflect differences in inflammatory activity. In addition, MBLmay aggravate local and systemic inflammation throughcomplement activation \[[@pone.0130665.ref040]\] and modulation of proinflammatorycytokine production \[[@pone.0130665.ref041]\]. We can speculate that high levels of MBL and subsequent complement activation will result in a net proinflammatory state, potentiating allograft damage, leading downstream to chronic allograft dysfunction. It could thus be hypothesized that in diabetic patients, high levels of MBL may contribute to the development of DR through aggravated complement activation. Thirdly, oxidative stress leading to changes in cell surfaceglycosylations may activate the complement system viaMBL \[[@pone.0130665.ref040]\], and MBL binding to fructoselysine and the ensuing complement activation may provide a physiopathological link between enhanced glycation and complement activation in diabetes \[[@pone.0130665.ref042]\]. Interestingly, we found that there was a modest positive correlation between levels of MBL and HBA1c (P\<0.0001).

A number of issues have to be taken into account wheninterpreting the results of the present study. Firstly, without serial measurement of the circulating MBL, this study yielded no data regarding when and how long of MBL was elevated in these patients. Additionally, it should be investigated whether serial MBL testing further improves the risk stratification of these patients. Secondly, the samples were also geographically limited, potentially limiting the generalizability of our results. Larger studies are needed to confirm our results and elucidate the underlying mechanisms. Thirdly, MBL genotypes were not determined. Those results should be useful to explain the differences MBL concentration between studies. Lastly, this was only a preliminary study; further studies should investigate whether MBL can help physicians tailor the therapy in view of the relative risk and allocate resources accordingly and whether this strategy might affect DR outcome.

Conclusions {#sec013}
===========

The present study demonstrated that serum MBL level was an independent risk factor for DR and VDTR in Chinese patients with T2DM, suggesting a possible role of MBL in the pathogenesis of DR complications. We suggested that further studies should be carried out with respect to what was the cause of the increased MBL levels and the role in the pathology of the DR.
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